TPX2 Antibody (Rabbit mAb) [C1B23]

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:1000 IHC1:1000 IF1:50 FCM1:50

Application
WB, IHC, IF, FCM

Reactivity
Mouse, Rat, Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
86 kDa 100 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
TPX2 Antibody (Rabbit mAb) [C1B23] detects endogenous levels of total TPX2 protein.

Clone
C1B23

Synonym(s)
C20orf1, C20orf2, DIL2, HCA519, TPX2, Protein fls353, Restricted expression proliferation-associated protein 100, DIL-2, p100

Background
Targeting protein for Xklp2 (TPX2) is a Ran-regulated microtubule-associated protein that localizes to the nucleus in interphase and to spindle microtubules during mitosis, where it functions as a key factor for spindle assembly, chromosome segregation and maintenance of genomic stability in dividing cells. The protein contains multiple coiled-coil and microtubule-binding regions and a C‑terminal Aurora A–activating domain; TPX2 binds and activates Aurora A kinase, protects it from dephosphorylation and targets it to spindle microtubules, thereby coordinating microtubule nucleation, stabilization and centrosome-independent spindle formation in a RanGTP-dependent manner. TPX2 also interacts with kinesin motors such as Xklp2 and Eg5, integrating motor activity with microtubule dynamics to ensure bipolar spindle formation and proper alignment of chromosomes at metaphase. In hepatocellular carcinoma, TPX2 is highly expressed in tumor tissues compared with adjacent non-tumoral liver, and elevated TPX2 correlates with poor prognosis; siRNA-mediated knockdown of TPX2 in HCC cell lines reduces cell growth, induces G2/M arrest, promotes apoptosis and inhibits epithelial–mesenchymal transition, demonstrating that TPX2 supports proliferation, survival and invasive behavior in these tumors. Detailed analysis of TPX2-depleted HCC cells shows increased levels of pro-apoptotic and DNA damage–related proteins including Bax, p53, caspase‑3 and caspase‑8, together with upregulation of the epithelial marker E‑cadherin and downregulation of N‑cadherin, β‑catenin, MMP‑2, MMP‑9 and the EMT transcription factor Slug, indicating that TPX2 influences cell-cycle and apoptotic machinery and modulates EMT-associated signaling networks. TPX2 knockdown also reduces phosphorylation of Akt and ERK, linking TPX2-dependent mitotic functions to activation of PI3K/Akt and MAPK pathways that drive tumor formation and progression in HCC. Across multiple solid tumors including colon, gastric and endometrial cancers, TPX2 overexpression is consistently associated with high proliferative indices, increased metastasis and poor survival, and integrative analyses identify TPX2-centered co-expression networks and TPX2/TTK mitotic checkpoint modules as key drivers of aggressive disease, making TPX2 a robust proliferation- and mitosis-related biomarker.

Background

Targeting protein for Xklp2 (TPX2) is a Ran-regulated microtubule-associated protein that localizes to the nucleus in interphase and to spindle microtubules during mitosis, where it functions as a key factor for spindle assembly, chromosome segregation and maintenance of genomic stability in dividing cells. The protein contains multiple coiled-coil and microtubule-binding regions and a C‑terminal Aurora A–activating domain; TPX2 binds and activates Aurora A kinase, protects it from dephosphorylation and targets it to spindle microtubules, thereby coordinating microtubule nucleation, stabilization and centrosome-independent spindle formation in a RanGTP-dependent manner. TPX2 also interacts with kinesin motors such as Xklp2 and Eg5, integrating motor activity with microtubule dynamics to ensure bipolar spindle formation and proper alignment of chromosomes at metaphase. In hepatocellular carcinoma, TPX2 is highly expressed in tumor tissues compared with adjacent non-tumoral liver, and elevated TPX2 correlates with poor prognosis; siRNA-mediated knockdown of TPX2 in HCC cell lines reduces cell growth, induces G2/M arrest, promotes apoptosis and inhibits epithelial–mesenchymal transition, demonstrating that TPX2 supports proliferation, survival and invasive behavior in these tumors. Detailed analysis of TPX2-depleted HCC cells shows increased levels of pro-apoptotic and DNA damage–related proteins including Bax, p53, caspase‑3 and caspase‑8, together with upregulation of the epithelial marker E‑cadherin and downregulation of N‑cadherin, β‑catenin, MMP‑2, MMP‑9 and the EMT transcription factor Slug, indicating that TPX2 influences cell-cycle and apoptotic machinery and modulates EMT-associated signaling networks. TPX2 knockdown also reduces phosphorylation of Akt and ERK, linking TPX2-dependent mitotic functions to activation of PI3K/Akt and MAPK pathways that drive tumor formation and progression in HCC. Across multiple solid tumors including colon, gastric and endometrial cancers, TPX2 overexpression is consistently associated with high proliferative indices, increased metastasis and poor survival, and integrative analyses identify TPX2-centered co-expression networks and TPX2/TTK mitotic checkpoint modules as key drivers of aggressive disease, making TPX2 a robust proliferation- and mitosis-related biomarker.

References
https://pubmed.ncbi.nlm.nih.gov/28069036/ https://pubmed.ncbi.nlm.nih.gov/24556998/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%